There are several advantages of hiPSC-CD34+ cells over those isolated from peripheral blood CD34+ cells: (1) iPSCs allow the generation of large numbers of CD34+ cells and the potential for long term cryogenic storage for immediate availability; (2) iPSC are considered “rejuvenated” and lose many of their aging features and epigenetic markers that are associated with disease [40,41]; (3) iPSC-derived cells have been shown to be less immunogenic than native phenotype [42,43]; and (4) iPSC allow the possibility of isogenic modification [44] to correct the genetic variants associated with AMD. The gene discussed is CD34; the disease is age-related macular degeneration.